The recent Dexcom G7 security incident involves three critical facts patients should understand. First, the stolen sensors were manufacturing rejects that failed quality control standards and were never approved for patient use—these were not approved devices diverted from legitimate supply chains. Second, the FDA has issued an official safety alert regarding potentially compromised devices, recommending verification of device authenticity. Third, patients should contact their healthcare providers to confirm their current sensor legitimacy and discuss appropriate next steps.
For continuous glucose monitoring users, verification is straightforward: consult your healthcare provider or Dexcom directly to confirm your device serial numbers and batch information. Patients should not discontinue glucose monitoring without medical guidance, as maintaining glycemic control remains essential. Healthcare providers are advised to maintain current inventory records and verify device authenticity through official Dexcom channels. This incident highlights the importance of supply chain integrity in medical device distribution and underscores patient advocacy in device security.
Read the full article on GMJ Newsroom.
Was this article helpful?
